Compare Peloton Interactive Inc (PTON) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Recursion Pharmaceuticals Inc — how do they compare? Peloton Interactive Inc trades at $5.06 (market cap $2.21B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Peloton Interactive Inc is the larger of the two by market cap, and Peloton Interactive Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PTON | RXRX | |
|---|---|---|
Market Cap | $2.21B | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.00 | $6.79 |
52-Week Low | $3.71 | $2.84 |
Enterprise Value | $2.71B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $5.04, down 6.67% amid bearish technical signals and mixed fundamentals. The company achieved its first full-year net profit in fiscal 2026 with a 2.58% net income margin, though revenue declined to $2.49B in 2025. Analyst sentiment is divided with a 50% buy rating but a consensus price target of $7.25, while technical indicators show strong bearish momentum with all moving averages signaling sell.
The outlook remains cautious as PTON balances profitability gains against subscriber declines and weak revenue growth. Investment opportunity exists if cost-cutting sustains margins, but risks include high debt load, competitive pressures, and insider selling activity. The stock trades near key support levels with institutional sentiment mixed.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
